PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of hippokratiaLink to Publisher's site
 
Hippokratia. 2010 Jul-Sep; 14(3): 164–169.
PMCID: PMC2943353

Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer

Abstract

The importance of the bone microenvironment to the pathophysiology and morbidity associated with prostate cancer bone metastasis is becoming increasingly apparent. Significant alterations take place in the microenvironment of bone, which disturb the normal coupling that exists between bone resorption and bone formation. Consequently, a better understanding of the mechanisms that interact at the molecular level will definitely result in more effective therapy for patients with this devastating complication of prostatic carcinoma. This review will discuss the diagnostic and predictive implications of various collagenous and non-collagenous bone markers, along with the novel markers of osteoclastogenesis and other matrix enzymes such as metalloproteinases and growth factors responsible for the complex biochemical mechanisms that upregulate bone resorption/formation during the development of metastasis. Further prospective studies are needed to determine whether any of these markers measured longitudinally in prostate cancer patients without bone scan evidence of skeletal disease will ultimately predict those patients who will develop bone metastases from their malignancy. Nonetheless, from the clinical point of view it is important to know that these novel markers carry the potential to provide meaningful information for daily practice by using upper normal reference values as cut-offs for identifying patients with an increased risk of developing progressive bone disease or skeletal related events.

Keywords: Prostate cancer, bone metastases, bone turnover markers, type I collagen, RANKL, osteoprotegerin, review

The importance of the bone microenvironment to the pathophysiology and morbidity associated with prostate cancer bone metastasis (PCBM) is becoming increasingly apparent. At the same time the identification of new biochemical pathways that control it, has allowed for the development of novel approaches aimed at preventing the devastating complications of bone metastases. Bone metabolism is characterized by two opposite activities, the formation of new bone by osteoblasts and the resorption of old bone by osteoclasts. Both normally are tightly coupled in time and space in a sequence of events that define the same remodelling unit. In the patients with PCBM, significant alterations take place in the microenvironment of bone, which disturb the normal coupling that exists between bone resorption and bone formation. At the skeletal site of metastatic invasion, the bone metabolism is dysregulated and bone resorption or bone formation, or both, is upregulated1. To initiate successful preventive therapy it is thus imperative that the bone metastases are detected early. This review will discuss the diagnostic and predictive implications of various collagenous and non-collagenous bone markers, along with the novel markers of osteoclastogenesis and other matrix enzymes responsible for the complex biochemical mechanisms that upregulate bone resorption/formation during the development of bone metastasis in patients suffering from prostate cancer.

I. Traditional non-collagenous matrix proteins

Osteocalcin (OC) is a small non-collagenous matrix protein of bone that derives from new cellular synthesis and is a marker for bone formation; yet it is a specific marker of bone formation whenever formation and resorption are uncoupled. Increased serum osteocalcin reflects acceleration of osteoblastic activity and bone turnover2. Nonetheless, the significance of osteocalcin as a marker of PCBM is disputable mainly due to methodological heterogeneity and easy loss of the molecule's immunological activity3,4. Bone alkaline phosphatase (BALP) is a tetrameric protein located in the plasma membrane of osteoblasts that plays an active role in bone formation and skeletal mineralization. Yet, BALP proved particularly useful to indicate the presence of PCBM and was significant increased in such patients when compared with those without bone metastasis5,6. Despite its advantages in the diagnosis of PCBM, BSAP has been reported less predictive for skeletal complications or response to therapy when compared with a number of collagen-derived markers, probably due to the fact that serum levels of it also increase to balance localized or systemic increases in osteolytic activity or as an indication of bone formation to repair bone lesions that have responded to treatment7.

II. Byproducts of type I collagen synthesis and degradation

Type I collagen is the most abundant collagen in many soft tissues, and accounts for more than 90% of the bone matrix8. Procollagen type I is the biosynthetic precursor of type I collagen. It is larger in size and contains additional aminoacidic sequences at both ends with respect to its final product8. During bone formation and collagen molecule synthesis, the amino-terminal and carboxy- terminal procollagen I extension peptides (PINP and PICP, respectively) are cleaved, while the central part of the molecule, is incorporated into bone matrix1. The first C-telopeptide carboxy-terminal assay was developed for serum and termed carboxyterminal telopeptide of type I collagen (ICTP). This assay utilizes an antibody that recognizes a unique amino acid sequence in the a1 chain of type I collagen during collagen degradation9,10. Serum ICTP and CTx assay results do not always agree clinically. This is because the monoclonal antibodies used for these two C-telopetide assays are different and recognize different epitopes at the carboxy terminal end of these telopeptides11. The second C-telopeptide assay, called Crosslaps (CTx), recognizes an 8–amino acid sequence that contains an aspartate residue12. Recently, assays have also been developed to measure the process of mature bone resorption via crosslinking molecules resulting from the degradation of type I collagen. Bone resorption assays in urine and serum have also been developed with antibodies raised against the N-telopeptide to helix domain (NTx)13. Both NTx and CTx are 8 amino acid epitopes derived from the N-telopeptide or C-telopeptide of type I collagen respectively, are cleaved by cathepsin K and the rate of their release from bone is a useful reflection of the resorbing activity of osteoclasts14.

Collagen-derived biochemical markers have advantages because they are noninvasive, inexpensive, reflect turnover in the whole skeleton, and allow repeated evaluation. hese markers have been suggested for monitoring patients with already known PCBM, to guide decision making regarding the treatment15 and also to gauge the efficacy of treatment of metastatic bone disease13,15. Previous studies revealed that various bone markers such as OC, BALP, amino-terminal and carboxy-terminal propeptides and telopeptides of type I collagen are remarkably elevated in the serum of patients with PCBM and correlate with the extend of bone disease (EOD)16,17.

a. Bone formation markers (type I collagen propeptides)

Serum concentrations of type I collagen propeptides (PINP and PICP) have been shown to be elevated in PCBM1618. Ratios of different bone formation markers were proposed as sensitive clinical markers for judging the response to therapy of prostate cancer metastasized to bone4,19, because the degree of appearance of each marker shows a specific pattern during three osteoblast developmental phases, including osteoblast proliferation, matrix maturation, and mineralization. Serum levels of PICP and PINP are also known to be elevated in other diseases such as bone fracture20, osteomalacia21, Paget's disease22 and also in the chronic phase of hypertrophy in hypertensive patients23. Thus, careful assessment of their levels is required in patients who have combinations of these diseases.

Moreover, it has been reported that advanced-stage tumors which contain high-grade cancer cells tend to produce less prostate specific antigen (PSA) and actually release less PSA into the blood24. Thus, these propeptides may be useful for detecting bone metastases in some patients whose serum PSA levels are low. It is fair to say that patients with prostatic cancer who have high serum marker levels and low serum PSA should be carefully evaluated for metastatic spread to bone9.

b. Bone resorption markers (type I collagen telopeptides)

Although osteoblastic lesions are characteristic of prostate cancer, an osteolytic component has been confirmed in several reports. Bone resorption markers such as ICTP, CTx and NTx have been noted to be higher in patients with osteoblastic disease than in patients with osteolytic disease11,25.

Considering the first one, serum levels of ICTP were significantly higher in patients with PCBM compared with patients without bone involment or with a control group with benign prostate hyperplasia, whereas PSA was significantly higher both in patients with and without bone metastasis compared with the control group10. Indeed, ICTP appears to be superior to PICP for detection of bone metastasis, whereas PICP is better in terms of correlation of extend of bone disease (EOD)9. However, some shortcomings of serum ICTP levels in clinical application have been indicated: it is affected by the presence of metabolic bone disease, renal dysfunction, or hypercalcemia, which sometimes are found in advanced cancer patients9,10.

Increased NTx and CTx levels showed excellent sensitivity in discriminating between patients with and without bone metastases and there is now growing evidence to suggest that these resorption markers might be of use in assessing presence and extension of skeletal disease11,12,17. Albeit the NTx assay is perhaps the most predictive biochemical marker of PCBM4, both NTx and CTx typically are increased in patients with bone metastases compared with healthy controls17, and essentially seem to provide similar information11. Increased NTx and CTx levels also correlate with reduced response to systemic anticancer treatments26, or to local skeletal radiotherapy27. Finally, clinical studies have shown that the baseline collagen telopeptide levels in patients with only skeletal metastases may be prognostic with regard to the time to disease progression and overall survival4,5,28.

As regards skeletal complications (SRE), for patients with bone metastases, total and bone-specific BALP, PINP, NTx, ICTP and CTx were useful tools to predict and diagnose SRE in patients with PCBM under receiving zoledronic acid therapy25,29,30. These analyses suggest that reducing bone turnover should have a positive effect by delaying progression of bone lesions and possibly improving survival2931. An increase in bone marker levels often precedes an event by several months, thus providing another opportunity for treatment interventions7. In this regard, high marker levels at baseline or at any time during the course of the disease might indicate that more aggressive intervention strategies are needed to prevent skeletal morbidity.

c. Collagen markers limitations

Collagenous markers of bone resorption have been reported to exhibit marked biological circadian variation with a nadir during the day and in the afternoon and with a peak during the night and early morning hours32. Consequently, in order to obtain valid estimates of bone resorption markers, blood and urine sampling must be performed in the fasting state of individuals and within relatively narrow time frames (8–10 hours). Another source of variation for biochemical markers is the longterm variability found in an individual over days and months. Intra-individual short-term (3 days) and longterm (2 months) variation for urinary NTx has recently been found to be 13.1% and 15.6%, respectively. The corresponding numbers for serum NTx were 6.3% and 7.5%, respectively32. Factors that might affect these variations include dietary habits, smoking, exercise, and medication. Bisphosphonate treatment reduces the circadian variability by about 50% in magnitude31. Zoledronic acid in particular, causes even more pronounced decreases of bone resorption markers29,30. It should be noted, however, that absolute changes in marker values are often misleading if the interpretation does not take into account the respective marker's analytical and biological variability. To be clinically meaningful, changes in bone markers induced by therapeutic interventions need to exceed a predefined range of non specific variability. Changes below these marker-specific thresholds should be considered either ambiguous or non specific. any assays for bone turnover markers, independent of the matrix used, have not achieved satisfactory standardization. Yet at present, results for most markers of bone turnover cannot be compared among laboratories without previous cross-calibration. Consequently, reference methods and international standards need to be developed33.

Bone resorption markers do not appear to be as sensitive as standard imaging techniques such as bone scans, or other types of imaging studies for detecting bone metastases. Moreover, when there is a diagnostic suspicion of skeletal metastases, there is still a need to confirm and evidence the site of the localization by an imaging modality; especially for therapeutic decision-making it would still be reasonable to carry out diagnostic imaging. Whether the markers can be used to determine early bone involvement or micrometastases before the bone scan turns positive in high risk cancer patients still remains to be determined. Additional study on the effect of other therapeutic approaches such as irradiation, endocrine therapy and operation might be useful to clarify the significance of changes in bone metabolic markers.

III. Markers of osteoclastogenesis

The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) pathway has been identified as the main driving force for osteoclastogenesis and resulting bone resorption. Osteoprotegerin (OPG), a naturally occurring protein that inhibits bone resorption, is a critical regulator of osteoclastogenesis, by inhibiting stimulation of osteoclast differentiation through the RANK/RANKL interaction. It is very promising in blocking the so called "vicious cycle" between bone resorption and tumor proliferation that takes place during tumor development in bone site34. Indeed, high rates of RANKL/RANK/OPG driven bone resorption correlate with more aggressive, advanced, metastatic prostate carcinoma and an increased risk of skeletal morbidity, whilst many current studies have theorized that blocking osteoclast activity and differentiation via the inhibition of RANK/RANKL/OPG interaction could be a treatment option for osteolytic diseases, including malignancies that have an osteolytic component like the prostate cancer35,36. Recently, a fully human monoclonal antibody against RANKL (denosumab) has been developed and is currently under multiple phase III clinical trials; denosumab interferes with RANK signalling by blocking RANKL and, just like OPG, preventing RANK activation37. Further studies are needed to determine the antitumor effect and safety of this antibody38.

IV. Other enzymes of bone matrix

One other family of enzymes that has been shown to play a role in tumor progression is the matrix metalloproteinase (MMP) family, also known as matrixins. The main physiologic function of MMPs is degradation of the extracellular matrix. In addition, MMPs are thought to promote the growth of tumor cells once they have metastasized39. Numerous studies have shown that the higher the MMP expression in the tumor, the more aggressive the cancer. The matrix metalloproteinases MMP-2, MMP-7 and MMP-9 are highly expressed in the tumorbone microenvironment and their activities were closely correlated with the invasiveness of the androgen-dependent and androgen-refractory prostate cancer cells3941. Recent clinical trials have been initiated on MMP-inhibitors known to down-regulate MMPs and suppress the invasive and metastatic potential in many tumor-derived cell lines40,42. Their usefulness as additional markers of bone metastasis remains to be better defined.

Angiogenesis is a critical process for cancer progression. Various growth factors such as the fibroblast growth factor 8 (FGF-8)43, the angiogenesis-related vascular endothelial growth factor (VEGF)44 and the transforming growth factor beta(1) [TGF-beta(1)]45, along with activin-A46 and macrophage-inhibitory cytokine-1 (MIC-1)47 (both members of the TGF-beta superfamily), are significant prognostic factors of PCBM. Moreover, insulin-like growth factors I, II and III (IGF-1, IGF-2 and IGF-3)48, along with macrophage colony-stimulating factor (M-CSF) and colony-stimulating factor-1 receptor (CSF-1R)49 also predict cancer stage and prognosis. Bone-morphogenetic protein-6 (BMP-6) overexpression has been shown to increase the aggressiveness and invasiveness of prostate cancer cells50. Bone sialoprotein (BSP) is a secreted glycoprotein found in mineralized tissues. However, elevated BSP expression in breast and prostate primary carcinomas is directly correlated with increased bone metastases and tumor progression51. The endothelin (ET) axis represents another novel and exciting target in the treatment of prostate cancer. ET-1, acting primarily through the endothelin-A receptor, is integrally involved in prostate cancer progression, including cell growth, inhibition of apoptosis, angiogenesis and development of bone metastases. Biological activity of selective ET-1 antagonists in patients with prostate cancer has been shown by the suppression of biochemical markers of prostate cancer progression in bone and a delay in time to disease progression in patients with PCBM52. The Src (a proto-oncogene tyrosine-protein kinase) has a definite role in the cancer cell proliferation, invasion, and migration. Encouraging results have been obtained in recent preclinical and clinical studies using inhibitors of Src in prostate cancer53. Parathyroid hormone-related peptide (PTHrP) is a regulatory protein associated with osteoclast stimulation in bone. The high frequency of PTHrP expression in PCBM is consistent with a role in the pathogenesis of bone metastases54. Serum tartrate-resistant acid phosphatase (TRACP) can also be considered a useful predictor of bone metastases in prostate cancer, albeit less specific than tALP55. Plasma levels of urokinase-type plasminogen activator (uPA) are associated with features of biologically aggressive prostate cancer and disease progression56. Serum interleukin-6 (IL-6), cystatin C (an endogenous inhibitor of cysteine proteinase cathepsin K) and serum chromogranin A (sCgA), along with cell membrane antigens like the gastrin-releasing peptide receptor (GRPR), the prostate stem cell antigen (PSCA), and the prostate-specific membrane antigen (PSMA), are expressed in prostate cancer and they are all novel attractive targets for new diagnostic and therapeutic applications5759. Further diagnostic, prognostic or predictive serological candidate prostate cancer biomarkers are various cytokines or chemokines, such as serum progastrinreleasing peptide60, alpha-2 macroglobulin (alpha-2M)61, cathepsin-D (CatD)62, the positive nuclear factor kappa-B (NF-Kb)63, plasma osteopontin (OPN)64, neuron-specific enolase (NSE)65 and even C-reactive protein (CRP)66.

Conclusions

In conclusion, the determination of novel bone turnover markers like byproducts of type I collagen synthesis and degradation, markers of osteoclastogenesis or matrix metalloproteinases and many other cytokines might be available for early diagnosis and follow-up of PCBM in the foreseeable future. Further prospective studies are needed to determine whether any of these markers measured longitudinally in prostate cancer patients without bone scan evidence of skeletal disease will ultimately predict those patients who later develop bone metastases from their malignancy. Nonetheless, from the clinical point of view it is important to know that these novel markers carry the potential to provide meaningful information for daily practice by using upper normal reference values as cut-offs for identifying patients with an increased risk of developing progressive bone disease or skeletal related events. Importantly also, in case of established skeletal disease, progressively or excessively high levels of such bone markers could alert for institution, re-institution, intensification or alteration of chemotherapy, hormone therapy, or bisphosphonate treatment. A better understanding of the mechanisms that interact at the molecular level will definitely result in more effective therapy for patients with this devastating complication of prostate cancer.

References

1. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer. 2002;94:2521–2533. [PubMed]
2. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 1994;9:255–264. [PubMed]
3. Arai Y, Takeuchi H, Oishi K, Yoshida O. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate. 1992;20:169–177. [PubMed]
4. Zafeirakis A, Papatheodorou G, Arhontakis A, Gouliamos A, Vlahos L, Limouris GS. Predictive implications of bone turnover markers after palliative treatment with (186) Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases. Eur J Nucl Med Mol Imaging. 2010;37:103–113. [PubMed]
5. Jung K, Lein M, Stephan C, Von H[var phi]sslin K, Semjonow A, Sinha P, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with metastatic spread: diagnostic and prognostics implications. Int J Cancer. 2004;111:783–791. [PubMed]
6. Wolff JM, Ittel TH, Borchers H, Boekels O, Jakse G. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Anticancer Res. 1999;19:2653–2655. [PubMed]
7. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69. [PubMed]
8. Miyahara M, Njieha FK, Prockop DI. Formation of collagen fibrils in vitro by cleavage of procollagen with procollagen proteinases. J Biol.Chem. 1982;257:8442–8448. [PubMed]
9. Akimoto S, Akakura K, Shimazaki J. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Jpn J Clin Oncol. 1996;26:157–163. [PubMed]
10. Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T, et al. Use of Bone Turnover Marker, Pyridinoline Cross-Linked Carboxyterminal Telopeptide of Type I Collagen (ICTP), in the Assessment and Monitoring of Bone Metastasis in Prostate Cancer. The Prostate. 1999;39:1–7. [PubMed]
11. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, et al. Prospective evaluation of the peptide-bound collagen Type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002;20:850–856. [PubMed]
12. Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, et al. Clinical evaluation of the serum Crosslaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem. 1998;44:2290–2300. [PubMed]
13. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res. 1999;14:792–801. [PubMed]
14. Herrmann M, Seibel M. The amino- and carboxyterminal crosslinked telopeptides of collagen type I, NTX-I and CTX-I: A comparative review. Clinica Chimica Acta. 2008;393:57–75. [PubMed]
15. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997;157:539–543. [PubMed]
16. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology. 2003;61:993–998. [PubMed]
17. Zafeirakis A, Papatheodorou GA, Limouris GS. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases. Nucl Med Commun. 2010;31:249–253. [PubMed]
18. Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol. 2007;178:849–853. [PubMed]
19. Koizumi M, Yonese J, Fukui I, Ogata E. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol. 2002;167:1863–1866. [PubMed]
20. Joerring S, Jensen LT, Andersen GR, Johansen JS. Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch Orthop Trauma Surg. 1992;111:265–267. [PubMed]
21. Li F, Iqbal J, Wassif W, Kaddam I, Moniz C. Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int. 1994;55:90–93. [PubMed]
22. Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL. Serum levels of type I and III procollagen fragments in Paget's disease of bone. Clin Endocrinol Metab. 1984;58:110–120. [PubMed]
23. Alla F, Kearney-Schwartz A, Radauceanu A, Das Dores S, Dousset B, Zannad F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diadetes. European Journal of Heart Failure. 2006;8:147–153. [PubMed]
24. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143:747–752. [PubMed]
25. Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res. 2005;25:1457–1463. [PubMed]
26. Brown JE, Ellis SP, Gutcher SA. Using bone turnover markers to direct bisphosphonate therapy: Is this a feasible approach? Cancer Treat Rev. 2005;31:30.
27. Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355:1428–1429. [PubMed]
28. Costa L, Demers LM, Gouveia A. Correlation of urinary N-telopeptide levels with progression of bone metastases: a prospective study. Cancer. 2000;88:3094.
29. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113:193–201. [PubMed]
30. Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, et al. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate. 2009;69:624–632. [PubMed]
31. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol. 2007;34:17–23. [PubMed]
32. Chesnut CH., III . Sources of biological bone marker variation. In: Eastell R, Baumann M, Hoyle NR, editors. Bone markers: Biochemical and clinical perspectives. London: Martin Dunitz; 2001. pp. 119–121.
33. Seibel M, Lang M, Geilenkeuser W-J. Interlaboratory Variation of Biochemical Markers of Bone Turnover. Clinical Chemistry. 2001;47:1443–1450. [PubMed]
34. Yonou H, Horiguchi Y, Ohno Y, Namiki K, Yoshioka K, Ohori M, et al. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. Prostate. 2007;67:840–848. [PubMed]
35. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62:1619–1623. [PubMed]
36. Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. BJU Int. 2008;101:1071–1075. [PubMed]
37. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care. 2008;2:197–203. [PubMed]
38. Ando K, Mori K, Rdini F, Heymann D. RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol. 2008;5:263–268. [PMC free article] [PubMed]
39. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7:14–23. [PubMed]
40. Thiolloy S, Halpern J, Holt GE, Schwartz HS, Mundy GR, Matrisian LM, Lynch CC. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res. 2009;69:6747–6755. [PMC free article] [PubMed]
41. Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, et al. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res. 2007;27:1519–1525. [PubMed]
42. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006;12:1556–1563. [PubMed]
43. Valta MP, Tuomela J, Bjartell A, Valve E, Vδδnδnen HK, Hδrk[var phi]nen P. FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer. 2008;123:22–31. [PubMed]
44. Peyromaure M, Camparo P, Badoual C, Descazeaud A, Dinh-Xuan AT. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int. 2007;99:1150–1153. [PubMed]
45. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001;19:2856–2864. [PubMed]
46. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006;23:117–122. [PubMed]
47. Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, Parpala T, et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev. 2007;16:532–537. [PubMed]
48. Kimura T, Kuwata T, Ashimine S, Yamazaki M, Yamauchi C, Nagai K, et al. Targeting of bone-derived insulin-like growth factor- II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res. 2010;16:121–129. [PMC free article] [PubMed]
49. Richardsen E, Uglehus RD, Due J, Busch C, Busund LT. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology. 2008;53:30–38. [PubMed]
50. Darby S, Cross SS, Brown NJ, Hamdy FC, Robson CN. BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J Pathol. 2008;214:394–404. [PubMed]
51. Gordon JA, Sodek J, Hunter GK, Goldberg HA. Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells. J Cell Biochem. 2009;107:1118–1128. [PubMed]
52. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12:6296s–6300s. [PubMed]
53. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int. 2009;103:434–440. [PubMed]
54. Bryden AA, Islam S, Freemont AJ, Shanks JH, George NJ, Clarke NW. Parathyroid hormone-related peptide: expression in prostate cancer bone metastases. Prostate Cancer Prostatic Dis. 2002;5:59–62. [PubMed]
55. Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, et al. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol. 2005;44:742–747. [PubMed]
56. Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thóroff JW, et al. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. BJU Int. 2009;104:29–34. [PubMed]
57. Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol. 2009;26:10–15. [PubMed]
58. Zissimopoulos A, Bantis A, Sountoulides P, Giannakopoulos S, Kalaitzis C, Agelonidou E, et al. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. Hell J Nucl Med. 2009;12:234–237. [PubMed]
59. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69:1101–1108. [PubMed]
60. Yashi M, Nukui A, Kurokawa S, Ochi M, Ishikawa S, Goto K, et al. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate. 2003;56:305–312. [PubMed]
61. Kanoh Y, Ohtani N, Mashiko T, Ohtani S, Nishikawa T, Egawa S, et al. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer. Anticancer Res. 2001;21:551–556. [PubMed]
62. Hara I, Miyake H, Yamanaka K, Hara S, Kamidono S. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression. Oncol Rep. 2002;9:1379–1383. [PubMed]
63. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int. 2003;91:417–420. [PubMed]
64. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate. 2007;67:330–340. [PubMed]
65. Hvamstad T, Jordal A, Hekmat N, Paus E, Fossε SD. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol. 2003;44:215–221. [PubMed]
66. Eklund CM, Tammela TL, Schleutker J, Hurme M. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk. Br J Cancer. 2009;100:1846–1851. [PMC free article] [PubMed]

Articles from Hippokratia are provided here courtesy of Hippokratio General Hospital of Thessaloniki